vicens Diaz-Brito

Dr. vicens Diaz-Brito

Parc Sanitari Sant Joan de Deu
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2018 in Clinical Infectious Diseases
Verified
Journal Article
Open access
MPMarta Di Pasquale
Marta Di Pasquale
GSGiovanni Sotgiu
Giovanni Sotgiu
AGAndrea Gramegna
Andrea Gramegna
DRDejan Radovanovic
Dejan Radovanovic
STSilvia Terraneo
Silvia Terraneo
LLLucía Labra
Lucía Labra
Background: The correct management of immunocompromised patients with pneumonia is debated. We evaluated the prevalence, risk factors, and characteristics of immunocompromised patients coming from the community with pneumonia. Methods: We conducted a secondary analysis of an international, multicenter study enrolling adult patients coming from the community with pneumonia and hospitalized in 222 hospitals in 54 countries worldwide. Risk factors for immunocompromise included AIDS, aplastic anemia, asplenia, hematological cancer, chemotherapy, neutropenia, biological drug use, lung transplantation, chronic steroid use, and solid tumor. Results: At least 1 risk factor for immunocompromise was recorded in 18% of the 3702 patients enrolled. The prevalences of risk factors significantly differed across continents and countries, with chronic steroid use (45%), hematological cancer (25%), and chemotherapy (22%) the most common. Among immunocompromised patients, community-acquired pneumonia (CAP) pathogens were the most frequently identified, and prevalences did not differ from those in immunocompetent patients. Risk factors for immunocompromise were independently associated with neither Pseudomonas aeruginosa nor non–community-acquired bacteria. Specific risk factors were independently associated with fungal infections (odds ratio for AIDS and hematological cancer, 15.10 and 4.65, respectively; both P = .001), mycobacterial infections (AIDS; P = .006), and viral infections other than influenza (hematological cancer, 5.49; P < .001). Conclusions: Our findings could be considered by clinicians in prescribing empiric antibiotic therapy for CAP in immunocompromised patients. Patients with AIDS and hematological cancer admitted with CAP may have higher prevalences of fungi, mycobacteria, and noninfluenza viruses.

1 December 2016 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
SAStefano Aliberti
Stefano Aliberti
LRLuis F Reyes
Luis F Reyes
Paola FaverioPaola Faverio
Paola Faverio
GSGiovanni Sotgiu
Giovanni Sotgiu
SDSimone Dore
Simone Dore
LLLucía Labra
Lucía Labra

1 January 2019 in Journal of Infection
Verified
Journal Article
Closed access
MWMarjan Wouthuyzen-Bakker
Marjan Wouthuyzen-Bakker
MSMarine Sebillotte
Marine Sebillotte
JLJose Lomas
Jose Lomas
ATAdrian Taylor
Adrian Taylor
EBEva Benavent
Eva Benavent
ASAlex Soriano
Alex Soriano

1 October 2011 in Vaccine
Verified
Journal Article
Closed access
FGFelipe García
Felipe García
JQJuan Carlos López Bernaldo de Quirós
Juan Carlos López Bernaldo de Quirós
Carmen Elena GomezCarmen Elena Gomez
Carmen Elena Gomez
BPBeatriz Perdiguero
Beatriz Perdiguero
JNJose L. Nájera
Jose L. Nájera
MMariano Esteban
Mariano Esteban

1 September 2019 in Journal of Infection
Verified
Journal Article
Closed access
MWMarjan Wouthuyzen-Bakker
Marjan Wouthuyzen-Bakker
MSMarine Sebillotte
Marine Sebillotte
JLJose Lomas
Jose Lomas
BKBenjamin Kendrick
Benjamin Kendrick
EPEva Benavent Palomares
Eva Benavent Palomares
ASAlex Soriano
Alex Soriano

25 February 2020 in Clinical Orthopaedics and Related Research
Verified
Journal Article
Closed access
MWMarjan Wouthuyzen-Bakker
Marjan Wouthuyzen-Bakker
MSMarine Sebillotte
Marine Sebillotte
KHKaisa Huotari
Kaisa Huotari
RSRosa Escudero Sánchez
Rosa Escudero Sánchez
EBEva Benavent
Eva Benavent
AVAndrea Vila
Andrea Vila
Background: Surgical débridement, antibiotics and implant retention (DAIR) is currently recommended by international guidelines for both early acute (postsurgical) and late acute (hematogenous) periprosthetic joint infections (PJIs). However, due to a different pathogenesis of infection, a different treatment strategy may be needed. Questions/purposes: (1) Compared with early acute PJIs, are late acute PJIs associated with a higher risk of DAIR failure? (2) When stratified by microorganism, is the higher risk of failure in late acute PJI associated with Staphylocococcus aureus infection? (3) When analyzing patients with S. aureus infection, what factors are independently associated with DAIR failure? Methods: In this multicenter observational study, early acute and late acute PJIs treated with DAIR were retrospectively evaluated and matched according to treating center, year of diagnosis, and infection-causing microorganism. If multiple matches were available, the early acute PJI diagnosed closest to the late acute PJI was selected. A total of 132 pairs were included. Treatment success was defined as a retained implant during follow-up without the need for antibiotic suppressive therapy. Results: Late acute PJIs had a lower treatment success (46% [60 of 132]) compared with early acute PJIs (76% [100 of 132]), OR 3.9 [95% CI 2.3 to 6.6]; p < 0.001), but the lower treatment success of late acute PJIs was only observed when caused by Staphylococcus spp (S. aureus: 34% versus 75%; p < 0.001; coagulase-negative staphylococci: 46% versus 88%; p = 0.013, respectively). On multivariable analysis, late acute PJI was the only independent factor associated with an unsuccessful DAIR when caused by S. aureus (OR 4.52 [95% CI 1.79 to 11.41]; p < 0.001). Conclusions: Although DAIR seems to be a successful therapeutic strategy in the management of early acute PJI, its use in late acute PJI should be reconsidered when caused by Staphylococcus spp. Our results advocate the importance of isolating the causative microorganism before surgery. Level of Evidence: Level III, therapeutic study.